In summary, the combined detection of SEPT9, SDC2, and ALX4 methylation status in plasma can cover multiple molecular pathways of tumor formation and further improvement in detection sensitivity, especially of the PL. The gene discussed is SEPTIN9; the disease is neoplasm.